Journey Medical Corporation DERM
Set alert
As of Nov 2, 1:15 PM ET
- YTD
- -36.23%
- 1 year
- -39.45%
- Open
- 5.22
- Prev close
- 5.17
- Mkt cap
- 138.86M
- Vol
- 58.65K
- Avg vol
- 199.98K
- EPS
- -0.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.90
- High
- 5.36
- Forward P/E
- -75.83
- Beta
- 0.00
- Short ratio
- 0.55
- Inst. own
- 24.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 5.50
- 200-d avg
- 4.83
- 1y target
- 10.00
YTD chart
Signals (49)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 29, 2026 | 4 days ago |
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 10, 2026 | 6 months ago |
| RSI: Oversold | Mar 26, 2026 | 7 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 9 months ago |
| SMA: Bullish | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 13, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
Key statistics
- Market cap
- 95.05M
- Enterprise value
- 96.37M
- Trailing P/E
- 0.00
- Forward P/E
- -75.83
- PEG ratio
- 0.00
- Price / sales
- 1.65
- Price / book
- 8.63
- EPS (TTM)
- -0.92
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -31.74%
- Revenue (TTM)
- 57.77M
- Revenue growth
- -57.60%
- Free cash flow
- -25.48M
- Total cash
- 22.46M
- Total debt
- 21.07M
- Return on equity
- -129.58%
- Shares outstanding
- 14.89M
- Short % of float
- 1.71%
- 50-day average
- 5.50
- 200-day average
- 4.83
Analyst view
Consensus: none
- Target (low)
- 9.00
- Target (mean)
- 10.00
- Target (high)
- 11.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.17 | -0.12 | +0.05 | +29.41% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | -0.17 | -0.02 | -13.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.26 | -0.53 | -0.27 | -103.85% |
| May 13, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -0.12 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 16, 2024 | Alliance Global Partners | init | — | Buy |
| Sep 7, 2023 | B. Riley Securities | reit | Buy | Buy |
| Jul 12, 2023 | B. Riley Securities | main | Buy | Buy |
| May 23, 2023 | B. Riley Securities | main | Buy | Buy |
| Mar 30, 2023 | B. Riley Securities | reit | — | Buy |
| Feb 25, 2022 | Cantor Fitzgerald | init | — | Overweight |
About Journey Medical Corporation
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- journeymedicalcorp.com
News
- HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
- Vireo Growth (OTCMKTS:VREOD) vs. Journey Medical (NASDAQ:DERM) Critical Contrast
- Journey Medical: A Small Pharma With A Large Growth Opportunity
- Journey Medical Corporation to Participate in September 2026 Investor Conferences
- ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
- Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
- B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
- Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings
Your note
Sign in to keep a note on DERM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENESCH JOSEPH | Chief Financial Officer | Sale | Jul 31, 2024 | 47,331 |
| HERSKOWITZ NEIL | Director | Stock Award(Grant) | Jul 7, 2024 | 81,445 |
| MARAOUI CLAUDE | Chief Executive Officer | Purchase | Mar 21, 2024 | 2,163,430 |
| PALEY JEFFREY | Director | Sale | Nov 27, 2023 | 70,727 |
| PEARCE MICHAEL COOPER | Director | Stock Award(Grant) | Jul 18, 2024 | 30,000 |
| ROSENWALD LINDSAY A | Director | Stock Award(Grant) | Jul 7, 2024 | 330,443 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.18% | 325,171 | 1.48M | Sep 29, 2024 |
| Cambridge Investment Research Advisors Inc. | 2.11% | 314,450 | 1.43M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.80% | 268,200 | 1.22M | Sep 29, 2024 |
| American Financial Group Inc. | 1.21% | 180,000 | 819.00K | Sep 29, 2024 |
| Envestnet Asset Management | 0.74% | 109,586 | 498.62K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.73% | 108,435 | 493.38K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.42% | 211,446 | 962.08K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.73% | 109,083 | 496.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 57,238 | 260.43K | Oct 30, 2024 |
| World Funds Tr-Perkins Discovery Fund | 0.15% | 22,000 | 100.10K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 18,124 | 82.46K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 17,985 | 81.83K | Oct 30, 2024 |